Synlogic announces the termination of their PKU study, and that they will no longer pursue a program for HCU. We understand that this news may be disappointing for those who have been eagerly following their progress. While this particular program may be ending, the initiation of a Phase III trial globally of pegtibatinase continues to provide hope for the community. Read Synlogic’s press release here.

1

0

4264

1

https://www.hcunetworkaustralia.org.au/4264-2/